Dementia and Alzheimer Disease

In a prior phase 1b/2 study, BXCL501 demonstrated statistically significant reductions in agitation measures with both the 30- and 60-mcg doses as measured by multiple scales with no severe or serious adverse events.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 6, 2022.

The findings in Alzheimer disease further elucidated the safety profile of AMX0035, as treatment emergent adverse events in the PEGASUS trial appeared to be largely disease driven.

Cerebrospinal fluid samples tested in a large cohort of patients at least 50 years of age with either mild cognitive impairment or Alzheimer disease showed high correlations between the Lumipulse G ß-Amyloid Ratio and PET status.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The effects of amyloid-ß and white matter hyperintensity volume on rates of neurodegeneration remained similar in cognitively normal individuals when they were assessed together as predictors in the same model.

A greater number of hypothalamic wake-promoting neurons were associated with a lower percentage of time in stage 2 of non-REM sleep and REM stages.

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is stroke.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 29, 2022.

A best-case analysis indicated that, for amyloid-positive patients diagnosed with MCI due to AD or mild AD dementia, lecanemab plus standard of care provided an additional gain of 0.75 in quality-adjusted life years.

Expert clinicians offer their insight on the associations between stroke and COVID-19, treatment for traumatic brain injury, the latest on aducanumab, priorities for research in migraine, and more, from the 2022 American Academy of Neurology Annual Meeting.

Following an NCD that will allow for Medicare coverage of the therapy only in NIH- and FDA-approved studies and trials, Biogen has pulled its application to the European Medicines Agency for aducanumab treatment in Alzheimer disease.

The neurologist and assistant professor at the University of Toronto discussed why elevating the voices of patients and caregivers is important to understanding and treating an individual with Alzheimer disease. [WATCH TIME: 3 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 22, 2022.

The neurologist and assistant professor at the University of Toronto provided insight on the differences between outcome measures for Alzheimer disease and how they factored into a new item-level analysis of aducanumab (Aduhelm; Biogen). [WATCH TIME: 3 minutes]

BioArctic CEO Gunilla Osswald, PhD, called the decision disappointing but noted that phase 1 data are supportive of ABBV-0805’s progression to phase 2 and that the company would “investigate options to continue the development” of the α-synuclein antibody.

Outcomes in TBI admission survivors at 24 months—including mortality, development of posttraumatic epilepsy, and use of antiseizure medications—were poorer for cases with early posttraumatic seizures after adjustment for confounders.

The neurologist and assistant professor at the University of Toronto detailed findings from a new analysis that supports meaningful treatment effect with aducanumab in Alzheimer disease. [WATCH TIME: 6 minutes]

The professor of neurology at NYU Langone Grossman School of Medicine discussed what high-potential repurposed medications could be an option to treat symptoms of COVID-19 and the realistic possibility of clinical trials. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is headache and migraine.

When controlling for insulin and body mass index, the association between physical activity and cerebral glucose metabolism remained unchanged, while the association with gray matter volume was lost.